Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a ...
Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced ...
Investing.com -- Genenta Science (NASDAQ:GNTA) stock soared 241.8% in premarket trading Friday after announcing a strategic collaboration with ANEMOCYTE focused on off-the-shelf lentiviral vector ...
HAMPTON, England--(BUSINESS WIRE)--Touchlight, a company pioneering enzymatic DNA production, a critical material in many new genetic medicine treatments, has completed the redevelopment and expansion ...
The Age of AI will rely on massive volumes of data that can be easily stored and retrieved—and bioscience may have an ingenious solution. A scientist examines a DNA (deoxyribonucleic acid) profile on ...
In the summer of 1812, French emperor Napoleon Bonaparte led about half a million soldiers to invade the Russian Empire. But ...
The partnership leverages Genenta's robust and well-tested LVV Plasmid DNA technology, a platform developed from the foundational research of Professor Luigi Naldini, co-founder of Genenta. This ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback